The MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) study is a phase 3 multicentric clinical trial for relapsed or refractory MF-SS. This evidence concerns the gene CCR4 and mycosis fungoides.